Ishita Drugs and Industries Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jagdishprasad Agrawal

İcra Kurulu Başkanı

₹5.1m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	no data
CEO sahipliği	8.7%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jagdishprasad Agrawal'un ücretlendirmesi Ishita Drugs and Industries'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	₹8m
Mar 31 2024	₹5m	₹5m	₹7m
Dec 31 2023	n/a	n/a	₹6m
Sep 30 2023	n/a	n/a	₹6m
Jun 30 2023	n/a	n/a	₹5m
Mar 31 2023	₹5m	₹5m	₹6m
Dec 31 2022	n/a	n/a	₹8m
Sep 30 2022	n/a	n/a	₹8m
Jun 30 2022	n/a	n/a	₹8m
Mar 31 2022	₹4m	₹4m	₹8m
Dec 31 2021	n/a	n/a	₹9m
Sep 30 2021	n/a	n/a	₹9m
Jun 30 2021	n/a	n/a	₹9m
Mar 31 2021	₹3m	₹3m	₹8m
Dec 31 2020	n/a	n/a	₹6m
Sep 30 2020	n/a	n/a	₹5m
Jun 30 2020	n/a	n/a	₹5m
Mar 31 2020	₹3m	n/a	₹5m
Dec 31 2019	n/a	n/a	₹5m
Sep 30 2019	n/a	n/a	₹4m
Jun 30 2019	n/a	n/a	₹4m
Mar 31 2019	₹3m	₹3m	₹4m
Dec 31 2018	n/a	n/a	₹3m
Sep 30 2018	n/a	n/a	₹3m
Jun 30 2018	n/a	n/a	₹3m
Mar 31 2018	₹2m	₹2m	₹2m

Tazminat ve Piyasa: Jagdishprasad 'nin toplam tazminatı ($USD 60.49K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 42.81K ).

Tazminat ve Kazançlar: Jagdishprasad 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jagdishprasad Agrawal

no data

Görev süresi

₹5,100,000

Tazminat

Mr. Jagdishprasad G. Agrawal serves as Chairman of the Board of Directors and Managing Director of Ishita Drugs and Industries Limited (formerly known as Ishita Drugs & Industries Limited) Mr. Agrawal has...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jagdishprasad Agrawal	Chairman & MD	no data	₹5.10m	8.7% ₹ 20.8m
Abha Agrawal	Non-Executive Director	32.5yrs	Veri yok	8.37% ₹ 20.0m
Govind Gupta	Independent Non Executive Director	no data	Veri yok	Veri yok
Arvind Sapkal	Independent Non-Executive Director	5yrs	Veri yok	Veri yok
Dhwani Solanki	Non Executive Independent Director	less than a year	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 524400 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Ishita Drugs and Industries Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ishita Drugs and Industries Limited Appoints Dhwani Solanki as an Independent Non-Executive Director

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2024

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

Insufficient new directors

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Ishita Drugs and Industries Limited Appoints Dhwani Solanki as an Independent Non-Executive Director

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2024

New major risk - Share price stability

First quarter 2025 earnings released: EPS: ₹0.49 (vs ₹0.46 in 1Q 2024)

Ishita Drugs and Industries Limited to Report Q1, 2025 Results on Aug 13, 2024

Investor sentiment improves as stock rises 20%

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 21%

Full year 2024 earnings released: EPS: ₹2.50 (vs ₹1.93 in FY 2023)

Ishita Drugs and Industries Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.40 (vs ₹0.38 in 3Q 2023)

Ishita Drugs and Industries Limited to Report Q3, 2023 Results on Feb 13, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹0.70 (vs ₹0.39 in 2Q 2023)

Investor sentiment improves as stock rises 16%

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹0.56 in 1Q 2023)

Ishita Drugs and Industries Limited to Report Q1, 2024 Results on Aug 12, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 20%

Full year 2023 earnings released: EPS: ₹1.93 (vs ₹2.69 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.38 (vs ₹0.52 in 3Q 2022)

Ishita Drugs and Industries Limited to Report Q3, 2023 Results on Feb 14, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹0.39 (vs ₹0.47 in 2Q 2022)

Investor sentiment improved over the past week

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.46 in 1Q 2022)

Ishita Drugs and Industries Limited to Report Q1, 2023 Results on Aug 13, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ishita Drugs and Industries Limited to Report Q3, 2022 Results on Feb 14, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS ₹0.47 (vs ₹0.51 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹2.77 (vs ₹1.83 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Company Secretary & Compliance Officer has left the company

Third quarter 2021 earnings released: EPS ₹0.46 (vs ₹0.41 in 3Q 2020)

Ishita Drugs and Industries Limited Announces Resignation of Vijay Shah from the Post of Company Secretary and Compliance Officer

Ishita Drugs and Industries Limited to Report Q3, 2021 Results on Feb 04, 2021

Investor sentiment improved over the past week

New 90-day high: ₹34.50

Investor sentiment improved over the past week

New 90-day high: ₹28.80

New 90-day high: ₹26.60

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: ₹24.75

Ishita Drugs & Industries Limited to Report Q1, 2021 Results on Aug 13, 2020

New 90-day high - ₹24.15

First quarter earnings released

New 90-day high - ₹18.60

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri